Array BioPharma (ARRY) up 25.8% AH as it signs a deal worth up to $467M ($45M up front and $422M...

|About: Array BioPharma Inc. (ARRY)|By:, SA News Editor

Array BioPharma (ARRY) up 25.8% AH as it signs a deal worth up to $467M ($45M up front and $422M in milestones) with Novartis (NVS) to license its experimental cancer drug candidates.